Thyroid Hormone T4 (Thyroxine) Suppression - Revision history

Lazy at 08:20, 18 January 2025

2025-01-18T08:20:52Z

← Older revision		Revision as of 01:20, 18 January 2025
Line 66:		Line 66:
	T3) in addition to standard treatment for newly diagnosed glioblastoma has started		T3) in addition to standard treatment for newly diagnosed glioblastoma has started
	recruiting in Tel-Aviv, Israel early in 2016 (NCT02654041).		recruiting in Tel-Aviv, Israel early in 2016 (NCT02654041).
	}}		\|overview=Thyroid Hormone T4 (Thyroxine) Suppression Therapy is an investigational treatment used off-label for cancer, particularly glioblastoma, which involves inducing chemical hypothyroidism to improve patient outcomes, with early studies showing median survival benefits. While not FDA-approved and associated with manageable side effects, ongoing clinical trials aim to further validate its efficacy and optimize treatment protocols.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:31:30Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:31, 12 November 2024
Line 9:		Line 9:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Thyroid Hormone T4 Suppression Therapy involves inducing chemical hypothyroidism via propylthiouracil or suppressing T4 levels with methimazole and supplementing with synthetic T3 (Cytomel) to mitigate cancer-promoting effects of thyroid hormones while avoiding hypothyroidism symptoms. Discovery of thyroid hormone receptors on cancer cells provides a mechanism for their potential cancer-promoting effects. Early studies and case reports suggest potential benefits in cancer treatment, especially glioblastoma, with notable long-term survival in some patients. Further research, including ongoing clinical trials, is needed to validate these findings and optimize treatment protocols.		\|notes=Thyroid Hormone T4 Suppression Therapy involves inducing chemical hypothyroidism via propylthiouracil or suppressing T4 levels with methimazole and supplementing with synthetic T3 (Cytomel) to mitigate cancer-promoting effects of thyroid hormones while avoiding hypothyroidism symptoms. Discovery of thyroid hormone receptors on cancer cells provides a mechanism for their potential cancer-promoting effects. Early studies and case reports suggest potential benefits in cancer treatment, especially glioblastoma, with notable long-term survival in some patients. Further research, including ongoing clinical trials, is needed to validate these findings and optimize treatment protocols.
	\|~~category~~=Hormones and Cancer Therapy		\|treatment_category=Hormones and Cancer Therapy
	\|links=NCT02654041		\|links=NCT02654041
	\|toxicity_level=2		\|toxicity_level=2

Lazy at 04:19, 6 April 2024

2024-04-06T04:19:18Z

@@ Line 1: / Line 1: @@
 {{TreatmentInfo
-|drug_name=Thyroid Hormone T4 Suppression Therapy
+|drug_name=Thyroid Hormone T4 (Thyroxine) Suppression
 |FDA_approval=No (Used off-label for cancer treatment; specific regimen for cancer not FDA-approved)
 |used_for=Investigational use in cancer treatment, particularly in glioblastoma, based on observations of improved outcomes with hypothyroid status
@@ Line 9: / Line 9: @@
 |usefulness_rating=3
 |notes=Thyroid Hormone T4 Suppression Therapy involves inducing chemical hypothyroidism via propylthiouracil or suppressing T4 levels with methimazole and supplementing with synthetic T3 (Cytomel) to mitigate cancer-promoting effects of thyroid hormones while avoiding hypothyroidism symptoms. Discovery of thyroid hormone receptors on cancer cells provides a mechanism for their potential cancer-promoting effects. Early studies and case reports suggest potential benefits in cancer treatment, especially glioblastoma, with notable long-term survival in some patients. Further research, including ongoing clinical trials, is needed to validate these findings and optimize treatment protocols.
-|category=Nutraceuticals
+|category=Hormones and Cancer Therapy
 |links=NCT02654041
 |toxicity_level=2
 |toxicity_explanation=The toxicity level of Thyroid Hormone T4 Suppression Therapy is rated as a 2, which indicates a low level of toxicity. This is because the therapy is designed to suppress the hormone levels in the body and replace them with a synthetic version to help fight cancer cells. The side effects, such as fatigue, are typically manageable, especially when the treatment is carefully monitored. Nonetheless, this therapy is not without potential side effects and it is applied off-label, hence it's necessary to discuss with your healthcare provider.
 }}

Lazy at 18:10, 27 March 2024

2024-03-27T18:10:39Z

← Older revision		Revision as of 11:10, 27 March 2024
Line 9:		Line 9:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Thyroid Hormone T4 Suppression Therapy involves inducing chemical hypothyroidism via propylthiouracil or suppressing T4 levels with methimazole and supplementing with synthetic T3 (Cytomel) to mitigate cancer-promoting effects of thyroid hormones while avoiding hypothyroidism symptoms. Discovery of thyroid hormone receptors on cancer cells provides a mechanism for their potential cancer-promoting effects. Early studies and case reports suggest potential benefits in cancer treatment, especially glioblastoma, with notable long-term survival in some patients. Further research, including ongoing clinical trials, is needed to validate these findings and optimize treatment protocols.		\|notes=Thyroid Hormone T4 Suppression Therapy involves inducing chemical hypothyroidism via propylthiouracil or suppressing T4 levels with methimazole and supplementing with synthetic T3 (Cytomel) to mitigate cancer-promoting effects of thyroid hormones while avoiding hypothyroidism symptoms. Discovery of thyroid hormone receptors on cancer cells provides a mechanism for their potential cancer-promoting effects. Early studies and case reports suggest potential benefits in cancer treatment, especially glioblastoma, with notable long-term survival in some patients. Further research, including ongoing clinical trials, is needed to validate these findings and optimize treatment protocols.
	\|category=Nutraceuticals ~~and Herbals~~		\|category=Nutraceuticals
	\|links=NCT02654041		\|links=NCT02654041
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=The toxicity level of Thyroid Hormone T4 Suppression Therapy is rated as a 2, which indicates a low level of toxicity. This is because the therapy is designed to suppress the hormone levels in the body and replace them with a synthetic version to help fight cancer cells. The side effects, such as fatigue, are typically manageable, especially when the treatment is carefully monitored. Nonetheless, this therapy is not without potential side effects and it is applied off-label, hence it's necessary to discuss with your healthcare provider.		\|toxicity_explanation=The toxicity level of Thyroid Hormone T4 Suppression Therapy is rated as a 2, which indicates a low level of toxicity. This is because the therapy is designed to suppress the hormone levels in the body and replace them with a synthetic version to help fight cancer cells. The side effects, such as fatigue, are typically manageable, especially when the treatment is carefully monitored. Nonetheless, this therapy is not without potential side effects and it is applied off-label, hence it's necessary to discuss with your healthcare provider.
	}}		}}

Lazy at 16:55, 27 March 2024

2024-03-27T16:55:05Z

← Older revision		Revision as of 09:55, 27 March 2024
Line 11:		Line 11:
	\|category=Nutraceuticals and Herbals		\|category=Nutraceuticals and Herbals
	\|links=NCT02654041		\|links=NCT02654041
			\|toxicity_level=2
			\|toxicity_explanation=The toxicity level of Thyroid Hormone T4 Suppression Therapy is rated as a 2, which indicates a low level of toxicity. This is because the therapy is designed to suppress the hormone levels in the body and replace them with a synthetic version to help fight cancer cells. The side effects, such as fatigue, are typically manageable, especially when the treatment is carefully monitored. Nonetheless, this therapy is not without potential side effects and it is applied off-label, hence it's necessary to discuss with your healthcare provider.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Thyroid Hormone T4 Suppression Therapy |FDA_approval=No (Used off-label for cancer treatment; specific regimen for cancer not FDA-approved) |used_for=Investigational use in cancer treatment, particularly in glioblastoma, based on observations of improved outcomes with hypothyroid status |clinical_trial_phase=Early clinical trials and case studies, including a phase 2 clinical trial in Israel (NCT02654041) |common_side_effects=Carefully monitore..."

2024-03-23T21:33:08Z

Created page with "{{TreatmentInfo |drug_name=Thyroid Hormone T4 Suppression Therapy |FDA_approval=No (Used off-label for cancer treatment; specific regimen for cancer not FDA-approved) |used_for=Investigational use in cancer treatment, particularly in glioblastoma, based on observations of improved outcomes with hypothyroid status |clinical_trial_phase=Early clinical trials and case studies, including a phase 2 clinical trial in Israel (NCT02654041) |common_side_effects=Carefully monitore..."

New page

{{TreatmentInfo
|drug_name=Thyroid Hormone T4 Suppression Therapy
|FDA_approval=No (Used off-label for cancer treatment; specific regimen for cancer not FDA-approved)
|used_for=Investigational use in cancer treatment, particularly in glioblastoma, based on observations of improved outcomes with hypothyroid status
|clinical_trial_phase=Early clinical trials and case studies, including a phase 2 clinical trial in Israel (NCT02654041)
|common_side_effects=Carefully monitored to avoid clinical symptoms of hypothyroidism; includes potential for fatigue if not properly managed
|OS_with=In early studies, hypothyroid patients showed median survival of 10.1 months compared to 3.1 months in non-hypothyroid patients. Remarkable long-term survivors in informal cohort studies with advanced cancer, including glioblastoma patients surviving 36 and 48 months.
|PFS_with=Not specifically documented; focus on overall survival improvements
|usefulness_rating=3
|notes=Thyroid Hormone T4 Suppression Therapy involves inducing chemical hypothyroidism via propylthiouracil or suppressing T4 levels with methimazole and supplementing with synthetic T3 (Cytomel) to mitigate cancer-promoting effects of thyroid hormones while avoiding hypothyroidism symptoms. Discovery of thyroid hormone receptors on cancer cells provides a mechanism for their potential cancer-promoting effects. Early studies and case reports suggest potential benefits in cancer treatment, especially glioblastoma, with notable long-term survival in some patients. Further research, including ongoing clinical trials, is needed to validate these findings and optimize treatment protocols.
|category=Nutraceuticals and Herbals
|links=NCT02654041
}}